Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
Want to see IN:THYROCARE full AI Analyst Report?
Top Page
Thyrocare Technologies Ltd
(THYROCARE)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹604.00
▲(31.56% Upside)
Action:Upgraded
Date:05/10/26
The score is driven primarily by strong financial quality (low leverage, improving returns, and solid cash generation). Technicals support the uptrend but are overheated, increasing short-term risk. High valuation (elevated P/E) meaningfully caps the overall score despite the dividend yield.
Positive Factors
Conservative balance sheet
Very low debt-to-equity (~0.09) and a strong equity base give the company durable financial flexibility. This supports sustained investment in central labs, buffer through downturns, and low refinancing risk, enabling long-term operational continuity and selective capital allocation.
Negative Factors
Margin volatility
Sharp year-to-year swings in gross and net margins create uncertainty in projecting long-term profitability. Durable planning for capex, pricing and staffing becomes harder; margin sensitivity to mix, input costs and discounts increases the risk that current margins may not persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low debt-to-equity (~0.09) and a strong equity base give the company durable financial flexibility. This supports sustained investment in central labs, buffer through downturns, and low refinancing risk, enabling long-term operational continuity and selective capital allocation.
Read all positive factors
Thyrocare Technologies Ltd (THYROCARE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹84.14B
Dividend Yield0.68%
Average Volume (3M)56.30K
Price to Earnings (P/E)51.1
Beta (1Y)0.63
Revenue Growth20.61%
EPS Growth77.73%
CountryIN
Employees1,693
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)24.16
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)9.48
Price to Sales (P/S)6.69
P/FCF Ratio28.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.9
Revenue Forecast (FY)₹9.67B
Thyrocare Technologies Ltd Business Overview & Revenue Model
Company Description
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across...
How the Company Makes Money
Thyrocare makes money mainly by charging for diagnostic tests processed in its laboratories. Its revenue model is built around high-volume, standardized pathology testing supported by centralized labs and an extensive sample collection and logisti...
Thyrocare Technologies Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.63B | 8.29B | 6.87B | 5.72B | 5.27B | 5.89B |
| Gross Profit | 5.90B | 4.13B | 4.96B | 1.81B | 3.63B | 4.19B |
| EBITDA | 2.45B | 2.62B | 2.04B | 1.48B | 1.31B | 2.64B |
| Net Income | 1.28B | 1.63B | 915.10M | 707.60M | 644.90M | 1.76B |
Balance Sheet | ||||||
| Total Assets | 6.80B | 7.47B | 6.93B | 6.44B | 6.33B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92B | 2.20B | 1.92B | 1.77B | 1.51B | 1.39B |
| Total Debt | 246.80M | 506.90M | 246.80M | 423.40M | 233.10M | 207.00M |
| Total Liabilities | 1.46B | 1.61B | 1.46B | 1.16B | 975.00M | 810.90M |
| Stockholders Equity | 5.34B | 5.86B | 5.47B | 5.27B | 5.34B | 5.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.11B | 1.95B | 1.46B | 1.06B | 856.60M | 755.80M |
| Operating Cash Flow | 1.27B | 2.16B | 1.91B | 1.68B | 1.29B | 1.13B |
| Investing Cash Flow | 47.10M | -260.80M | -525.20M | -912.80M | -389.90M | -235.70M |
| Financing Cash Flow | -1.18B | -1.70B | -1.30B | -848.00M | -861.80M | -894.10M |
Thyrocare Technologies Ltd Technical Analysis
Positive
459.10
Price Trends
448.94
Positive
426.07
Positive
432.75
Positive
Market Momentum
23.92
Positive
63.57
Neutral
36.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Positive. The current price of 459.1 is below the 20-day moving average (MA) of 504.36, above the 50-day MA of 448.94, and above the 200-day MA of 432.75, indicating a bullish trend. The MACD of 23.92 indicates Positive momentum. The RSI at 63.57 is Neutral, neither overbought nor oversold. The STOCH value of 36.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:THYROCARE.
Thyrocare Technologies Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹268.30B | 53.00 | ― | 0.89% | 12.25% | 3.57% | |
74 Outperform | ₹24.75B | 31.95 | ― | 0.16% | 16.08% | 14.59% | |
73 Outperform | ₹84.14B | 51.10 | ― | 0.68% | 20.61% | 77.73% | |
72 Outperform | ₹110.08B | 57.79 | ― | 0.21% | 23.64% | 29.96% | |
71 Outperform | ₹132.20B | 76.65 | ― | 0.20% | 19.49% | 20.50% | |
55 Neutral | ₹17.37B | 17.09 | ― | 0.38% | 7.75% | 30.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:THYROCARE
Thyrocare Technologies Ltd
528.65
196.83
59.32%
IN:KRSNAA
Krsnaa Diagnostics Limited
535.40
-137.49
-20.43%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,600.50
135.36
9.24%
IN:METROPOLIS
Metropolis Healthcare Ltd.
530.95
104.33
24.45%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,286.90
322.84
33.49%
IN:VIMTALABS
Vimta Labs Limited
554.10
69.05
14.24%
Thyrocare Technologies Ltd Corporate Events
Thyrocare Sets Record Date for ₹7 Final Dividend for FY 2025-26
Jun 4, 2026
Thyrocare Technologies has announced that its board has recommended a final dividend of ₹7 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming annual general meeting. The company has ...
Thyrocare Files Business Responsibility and Sustainability Report for FY 2025-26
Jun 4, 2026
Thyrocare Technologies Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26 in line with SEBI Listing Regulations. The report, forming part of the company’s annual report and filed on a s...
Thyrocare Shares AGM, Annual Report Links and Key Dividend Dates With Investors
Jun 4, 2026
Thyrocare Technologies Limited has notified stock exchanges that it has circulated a letter to shareholders who have not registered email addresses, providing web links to the notice of its 26th Annual General Meeting and the annual report for fin...
Thyrocare Publishes Audited FY26 Results in Line with SEBI Norms
May 9, 2026
Thyrocare Technologies Ltd has published its audited financial results for the quarter and full year ended March 31, 2026 in leading Marathi and English newspapers, in line with SEBI’s Listing Regulations. The company has also provided a QR ...
Thyrocare Receives ₹2.03 Crore Tax Demand, Plans to Contest
Mar 29, 2026
Thyrocare Technologies has disclosed that it received a notice of demand from the Income Tax Department’s Assessment Unit under Section 156 of the Income-tax Act for Assessment Year 2024-25, raising a tax demand of ₹2,02,82,260. The co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.